Table 2.

Radiographic manifestations, treatment and outcomes of patients with adenovirus pneumonia.

No	Radiographic manifestations	OI	Duration of dyspnea to IMV*	Duration of IMV*	Duration of IMV to ECMO†	Duration of ECMO*	IVIG (g/kg)	CRRT*	Antiviral agent	Serotype	Coinfection	Duration of ICU*	Duration of hospitalization*	Main complications and sequelae	Outcomes
1	Consolidations, pleural effusion	12.8	5	12	45.5	7	2	-	Oseltamivir	7	Negative	25	39	Plastic bronchitis, encephalatrophy	Survival
2	Consolidations, pleural effusion, atelectasis, bronchiectasis	18.9	5	13	22	9	2	-	Oseltamivir	NA	Influenza A virus, Mycoplasma	23	36	BO, hypertension	Survival
3	Consolidations, pleural effusion, bronchiectasis	28.6	7	15	24	8	4	-	Oseltamivir	NA	Stenotrophomonas maltophilia	42	77	BO, MOF, pancreatitis	Survival
4	Consolidations, pleural effusion, atelectasis	5.0	2	26	31	9	2.5	8	None	7	Negative	49	56	BO, MOF, pneumothorax, cognitive dysfunction	Survival
5	Consolidations, pleural effusion, bronchiectasis, pulmonary fibrosis	18.4	1	86	4	86	2	16	Acyclovir, oseltamivir	7	Mycoplasma, Aspergillus fumigatus	86	86	MOF, pneumothorax	Death (MOF)
6	Consolidations, pleural effusion, atelectasis, bronchiectasis	48.8	9	15	6	12	2.5	-	None	NA	Klebsiella pneumoniae	27	58	BO	Survival
7	Consolidations, pleural effusion, atelectasis	51.4	4	12	25	9	2	-	None	NA	Negative	28	28	BO, circuit clotting	Survival
8	Consolidations, pleural effusion, atelectasis	52.6	17	12	42	10	2	-	Oseltamivir	NA	Mycoplasma, Acinetobacter baumannii	12	28	Pneumorrhagia	Death (ARDS)

OI: oxygen index;

^*day;

^†hour; IMV, invasive mechanical ventilation; ECMO, extracorporeal membrane oxygenation; IVIG, intravenous immunoglobin; CRRT, continuous renal replacement therapy; NA, not available; ICU, intensive care unit; BO, bronchiolitis obliterans; MOF, multiple organ failure; ARDS, acute respiratory distress syndrome.